Similar articles

• Edaravone in ALS.

  Takahashi R. Takahashi R. Exp Neurol. 2009 Jun;217(2):235-6. doi: 10.1016/j.expneurol.2009.03.001. Epub 2009 Mar 10. Exp Neurol. 2009. PMID: 19285071 No abstract available.
• Edaravone: a new hope for deadly amyotrophic lateral sclerosis.

  Bhandari R, Kuhad A, Kuhad A. Bhandari R, et al. Drugs Today (Barc). 2018 Jun;54(6):349-360. doi: 10.1358/dot.2018.54.6.2828189. Drugs Today (Barc). 2018. PMID: 29998226 Review.
• Edaravone and its clinical development for amyotrophic lateral sclerosis.

  Takei K, Watanabe K, Yuki S, Akimoto M, Sakata T, Palumbo J. Takei K, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):5-10. doi: 10.1080/21678421.2017.1353101. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 28872907 Review.
• A safety analysis of edaravone (MCI-186) during the first six cycles (24 weeks) of amyotrophic lateral sclerosis (ALS) therapy from the double-blind period in three randomized, placebo-controlled studies.

  Kalin A, Medina-Paraiso E, Ishizaki K, Kim A, Zhang Y, Saita T, Wasaki M. Kalin A, et al. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):71-79. doi: 10.1080/21678421.2017.1362440. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 28872919 Clinical Trial.
• Open-label 24-week extension study of edaravone (MCI-186) in amyotrophic lateral sclerosis.

  WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP. WRITING GROUP ON BEHALF OF THE EDARAVONE (MCI-186) ALS 19 STUDY GROUP. Amyotroph Lateral Scler Frontotemporal Degener. 2017 Oct;18(sup1):55-63. doi: 10.1080/21678421.2017.1364269. Amyotroph Lateral Scler Frontotemporal Degener. 2017. PMID: 28872920 Clinical Trial.